|
1
|
Gonçalves DU, Proietti FA, Ribas JG,
Araújo MG, Pinheiro SR, Guedes AC and Carneiro-Proietti AB:
Epidemiology, treatment, and prevention of human T-cell leukemia
virus type 1-associated diseases. Clin Microbiol Rev. 23:577–589.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gessain A and Cassar O: Epidemiological
aspects and world distribution of HTLV-1 infection. Front
Microbiol. 3:3882012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Okayama A, Stuver S, Matsuoka M, Ishizaki
J, Tanaka G, Kubuki Y, Mueller N, Hsieh CC, Tachibana N and
Tsubouchi H: Role of HTLV-1 proviral DNA load and clonality in the
development of adult T-cell leukemia/lymphoma in asymptomatic
carriers. Int J Cancer. 110:621–625. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nagai M, Usuku K, Matsumoto W, Kodama D,
Takenouchi N, Moritoyo T, Hashiguchi S, Ichinose M, Bangham CR,
Izumo S, et al: Analysis of HTLV-I proviral load in 202 HAM/TSP
patients and 243 asymptomatic HTLV-I carriers: High proviral load
strongly predisposes to HAM/TSP. J Neurovirol. 4:586–593. 1998.
View Article : Google Scholar
|
|
5
|
Mori N: Cell signaling modifiers for
molecular targeted therapy in ATLL. Front Biosci (Landmark Ed).
14:1479–1489. 2009. View
Article : Google Scholar
|
|
6
|
Hall WW and Fujii M: Deregulation of
cell-signaling pathways in HTLV-1 infection. Oncogene.
24:5965–5975. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Surh Y-J: Cancer chemoprevention with
dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yadav VR, Prasad S, Sung B and Aggarwal
BB: The role of chalcones in suppression of NF-κB-mediated
inflammation and cancer. Int Immunopharmacol. 11:295–309. 2011.
View Article : Google Scholar
|
|
9
|
Gupta SC, Kim JH, Prasad S and Aggarwal
BB: Regulation of survival, proliferation, invasion, angiogenesis,
and metastasis of tumor cells through modulation of inflammatory
pathways by nutraceuticals. Cancer Metastasis Rev. 29:405–434.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee S-H, Choi W-C, Kim K-S, Park J-W, Lee
S-H and Yoon S-W: Shrinkage of gastric cancer in an elderly patient
who received Rhus verniciflua Stokes extract. J Altern Complement
Med. 16:497–500. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Woo S-M, Choi YK, Kim AJ, Cho S-G and Ko
S-G: p53 causes butein-mediated apoptosis of chronic myeloid
leukemia cells. Mol Med Rep. 13:1091–1096. 2016.
|
|
12
|
Zhang L, Yang X, Li X, Li C, Zhao L, Zhou
Y and Hou H: Butein sensitizes HeLa cells to cisplatin through the
AKT and ERK/p38 MAPK pathways by targeting FoxO3a. Int J Mol Med.
36:957–966. 2015.PubMed/NCBI
|
|
13
|
Bai X, Ma Y and Zhang G: Butein suppresses
cervical cancer growth through the PI3K/AKT/mTOR pathway. Oncol
Rep. 33:3085–3092. 2015.PubMed/NCBI
|
|
14
|
Mori N and Prager D: Transactivation of
the interleukin-1alpha promoter by human T-cell leukemia virus type
I and type II Tax proteins. Blood. 87:3410–3417. 1996.PubMed/NCBI
|
|
15
|
Zhang C, Ao Z, Seth A and Schlossman SF: A
mitochondrial membrane protein defined by a novel monoclonal
antibody is preferentially detected in apoptotic cells. J Immunol.
157:3980–3987. 1996.PubMed/NCBI
|
|
16
|
Khan N, Afaq F and Mukhtar H: Apoptosis by
dietary factors: The suicide solution for delaying cancer growth.
Carcinogenesis. 28:233–239. 2007. View Article : Google Scholar
|
|
17
|
Lim S and Kaldis P: Cdks, cyclins and
CKIs: Roles beyond cell cycle regulation. Development.
140:3079–3093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hayden MS and Ghosh S: Shared principles
in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dan HC, Sun M, Kaneko S, Feldman RI,
Nicosia SV, Wang H-G, Tsang BK and Cheng JQ: Akt phosphorylation
and stabilization of X-linked inhibitor of apoptosis protein
(XIAP). J Biol Chem. 279:5405–5412. 2004. View Article : Google Scholar
|
|
20
|
Vaira V, Lee CW, Goel HL, Bosari S,
Languino LR and Altieri DC: Regulation of survivin expression by
IGF-1/mTOR signaling. Oncogene. 26:2678–2684. 2007. View Article : Google Scholar
|
|
21
|
Zhang X, Tang N, Hadden TJ and Rishi AK:
Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta.
1813:1978–1986. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sizemore N, Leung S and Stark GR:
Activation of phosphatidylinositol 3-kinase in response to
interleukin-1 leads to phosphorylation and activation of the
NF-kappaB p65/RelA subunit. Mol Cell Biol. 19:4798–4805. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kamal A, Boehm MF and Burrows FJ:
Therapeutic and diagnostic implications of Hsp90 activation. Trends
Mol Med. 10:283–290. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kamihira S, Atogami S, Sohda H, Momita S,
Yamada Y and Tomonaga M: Significance of soluble interleukin-2
receptor levels for evaluation of the progression of adult T-cell
leukemia. Cancer. 73:2753–2758. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nishioka C, Takemoto S, Kataoka S,
Yamanaka S, Moriki T, Shoda M, Watanabe T and Taguchi H: Serum
level of soluble CD30 correlates with the aggressiveness of adult
T-cell leukemia/lymphoma. Cancer Sci. 96:810–815. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shimoyama M: Diagnostic criteria and
classification of clinical subtypes of adult T-cell
leukaemia-lymphoma. A report from the Lymphoma Study Group
(1984–87). Br J Haematol. 79:428–437. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tsukasaki K, Utsunomiya A, Fukuda H,
Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H,
Ueda R, et al Japan Clinical Oncology Group Study JCOG9801:
VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell
leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J
Clin Oncol. 25:5458–5464. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Morgan DO: Cyclin-dependent kinases:
Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol.
13:261–291. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lew DJ, Dulić V and Reed SI: Isolation of
three novel human cyclins by rescue of G1 cyclin (Cln) function in
yeast. Cell. 66:1197–1206. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bates S, Bonetta L, MacAllan D, Parry D,
Holder A, Dickson C and Peters G: CDK6 (PLSTIRE) and CDK4 (PSK-J3)
are a distinct subset of the cyclin-dependent kinases that
associate with cyclin D1. Oncogene. 9:71–79. 1994.PubMed/NCBI
|
|
31
|
Koff A, Giordano A, Desai D, Yamashita K,
Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR and Roberts
JM: Formation and activation of a cyclin E-cdk2 complex during the
G1 phase of the human cell cycle. Science. 257:1689–1694. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Weinberg RA: The retinoblastoma protein
and cell cycle control. Cell. 81:323–330. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ben-Neriah Y and Karin M: Inflammation
meets cancer, with NF-κB as the matchmaker. Nat Immunol.
12:715–723. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jost PJ and Ruland J: Aberrant NF-kappaB
signaling in lymphoma: Mechanisms, consequences, and therapeutic
implications. Blood. 109:2700–2707. 2007.
|
|
35
|
Viatour P, Merville MP, Bours V and
Chariot A: Phosphorylation of NF-kappaB and IkappaB proteins:
Implications in cancer and inflammation. Trends Biochem Sci.
30:43–52. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hess J, Angel P and Schorpp-Kistner M:
AP-1 subunits: Quarrel and harmony among siblings. J Cell Sci.
117:5965–5973. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pahl HL: Activators and target genes of
Rel/NF-kappaB transcription factors. Oncogene. 18:6853–6866. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Drysdale MJ, Brough PA, Massey A, Jensen
MR and Schoepfer J: Targeting Hsp90 for the treatment of cancer.
Curr Opin Drug Discov Devel. 9:483–495. 2006.PubMed/NCBI
|
